VC-backed Landos Biopharma goes public
Landos Biopharma, a developer of treatments for patients with autoimmune diseases, has raised about $100 million for its IPO after pricing its 6.25 million shares at $16 per share.
Landos Biopharma, a developer of treatments for patients with autoimmune diseases, has raised about $100 million for its IPO after pricing its 6.25 million shares at $16 per share.
Copyright PEI Media
Not for publication, email or dissemination